324 related articles for article (PubMed ID: 15788695)
1. Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia.
Raaijmakers MH; de Grouw EP; Heuver LH; van der Reijden BA; Jansen JH; Scheper RJ; Scheffer GL; de Witte TJ; Raymakers RA
Clin Cancer Res; 2005 Mar; 11(6):2436-44. PubMed ID: 15788695
[TBL] [Abstract][Full Text] [Related]
2. ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia.
Raaijmakers MH; de Grouw EP; van der Reijden BA; de Witte TJ; Jansen JH; Raymakers RA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3452-8. PubMed ID: 16740770
[TBL] [Abstract][Full Text] [Related]
3. The role of breast cancer resistance protein in acute lymphoblastic leukemia.
Plasschaert SL; van der Kolk DM; de Bont ES; Kamps WA; Morisaki K; Bates SE; Scheffer GL; Scheper RJ; Vellenga E; de Vries EG
Clin Cancer Res; 2003 Nov; 9(14):5171-7. PubMed ID: 14613996
[TBL] [Abstract][Full Text] [Related]
4. Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia.
van der Kolk DM; Vellenga E; Scheffer GL; Müller M; Bates SE; Scheper RJ; de Vries EG
Blood; 2002 May; 99(10):3763-70. PubMed ID: 11986234
[TBL] [Abstract][Full Text] [Related]
5. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.
van den Heuvel-Eibrink MM; van der Holt B; Burnett AK; Knauf WU; Fey MF; Verhoef GE; Vellenga E; Ossenkoppele GJ; Löwenberg B; Sonneveld P
Ann Hematol; 2007 May; 86(5):329-37. PubMed ID: 17340137
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
Benderra Z; Faussat AM; Sayada L; Perrot JY; Chaoui D; Marie JP; Legrand O
Clin Cancer Res; 2004 Dec; 10(23):7896-902. PubMed ID: 15585622
[TBL] [Abstract][Full Text] [Related]
7. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells.
Svirnovski AI; Shman TV; Serhiyenka TF; Savitski VP; Smolnikova VV; Fedasenka UU
Hematology; 2009 Aug; 14(4):204-12. PubMed ID: 19635183
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function.
Suvannasankha A; Minderman H; O'Loughlin KL; Nakanishi T; Greco WR; Ross DD; Baer MR
Leukemia; 2004 Jul; 18(7):1252-7. PubMed ID: 15208643
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML).
van den Heuvel-Eibrink MM; Wiemer EA; Prins A; Meijerink JP; Vossebeld PJ; van der Holt B; Pieters R; Sonneveld P
Leukemia; 2002 May; 16(5):833-9. PubMed ID: 11986944
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
[TBL] [Abstract][Full Text] [Related]
11. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
12. Nilotinib enhances the efficacy of conventional chemotherapeutic drugs in CD34⁺CD38⁻ stem cells and ABC transporter overexpressing leukemia cells.
Wang F; Wang XK; Shi CJ; Zhang H; Hu YP; Chen YF; Fu LW
Molecules; 2014 Mar; 19(3):3356-75. PubMed ID: 24651611
[TBL] [Abstract][Full Text] [Related]
13. [The relationship between multi-drug resistance and proportion of leukemia stem cells and expression of drug transporters in drug-resistant leukemia K562/ADM cells].
Yi J; Chen J; Sun J; Wei HL
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(25):1741-4. PubMed ID: 19862976
[TBL] [Abstract][Full Text] [Related]
14. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
Allen JD; van Loevezijn A; Lakhai JM; van der Valk M; van Tellingen O; Reid G; Schellens JH; Koomen GJ; Schinkel AH
Mol Cancer Ther; 2002 Apr; 1(6):417-25. PubMed ID: 12477054
[TBL] [Abstract][Full Text] [Related]
15. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporin A is a broad-spectrum multidrug resistance modulator.
Qadir M; O'Loughlin KL; Fricke SM; Williamson NA; Greco WR; Minderman H; Baer MR
Clin Cancer Res; 2005 Mar; 11(6):2320-6. PubMed ID: 15788683
[TBL] [Abstract][Full Text] [Related]
17. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
[TBL] [Abstract][Full Text] [Related]
18. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
Zhang YH; Li G; Yu J; Xu MS; Liu ZX
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
[TBL] [Abstract][Full Text] [Related]
19. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
Ji N; Yuan J; Liu J; Tian S
Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
[TBL] [Abstract][Full Text] [Related]
20. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties.
Jekerle V; Klinkhammer W; Reilly RM; Piquette-Miller M; Wiese M
Cancer Chemother Pharmacol; 2007 Jan; 59(1):61-9. PubMed ID: 16636798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
